Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199

1.

Appearance of vanD-positive Enterococcus faecium in a tertiary hospital in the Netherlands: prevalence of vanC and vanD in hospitalized patients.

Flipse J, von Wintersdorff CJH, van Niekerk JM, Jamin C, van Tiel FH, Hasman H, van Alphen LB.

Sci Rep. 2019 May 6;9(1):6949. doi: 10.1038/s41598-019-42824-4.

2.

Culture-free genotyping of Neisseria gonorrhoeae revealed distinct strains at different anatomical sites in a quarter of patients, the Netherlands, 2012 to 2016.

van der Veer BM, Wolffs PF, Hoebe CJ, Dukers-Muijrers NH, van Alphen LB.

Euro Surveill. 2018 Dec;23(50). doi: 10.2807/1560-7917.ES.2018.23.50.1800253.

3.

Detection of the plasmid-mediated colistin-resistance gene mcr-1 in faecal metagenomes of Dutch travellers.

von Wintersdorff CJ, Wolffs PF, van Niekerk JM, Beuken E, van Alphen LB, Stobberingh EE, Oude Lashof AM, Hoebe CJ, Savelkoul PH, Penders J.

J Antimicrob Chemother. 2016 Dec;71(12):3416-3419. Epub 2016 Aug 23.

PMID:
27559117
4.

Dissemination of Antimicrobial Resistance in Microbial Ecosystems through Horizontal Gene Transfer.

von Wintersdorff CJ, Penders J, van Niekerk JM, Mills ND, Majumder S, van Alphen LB, Savelkoul PH, Wolffs PF.

Front Microbiol. 2016 Feb 19;7:173. doi: 10.3389/fmicb.2016.00173. eCollection 2016. Review.

5.

A Flagellar Glycan-Specific Protein Encoded by Campylobacter Phages Inhibits Host Cell Growth.

Javed MA, Sacher JC, van Alphen LB, Patry RT, Szymanski CM.

Viruses. 2015 Dec 16;7(12):6661-74. doi: 10.3390/v7122964.

6.

Meticillin-resistant Staphylococcus aureus CC398 is an increasing cause of disease in people with no livestock contact in Denmark, 1999 to 2011.

Larsen J, Petersen A, Sørum M, Stegger M, van Alphen L, Valentiner-Branth P, Knudsen LK, Larsen LS, Feingold B, Price LB, Andersen PS, Larsen AR, Skov RL.

Euro Surveill. 2015;20(37). doi: 10.2807/1560-7917.ES.2015.20.37.30021.

7.

Trends in human leptospirosis in Denmark, 1980 to 2012.

van Alphen LB, Ethelberg S, Villumsen S, Krogfelt KA.

Euro Surveill. 2015 Mar 5;20(9). pii: 21054. No abstract available.

8.

Trends in human leptospirosis in Denmark, 1980 to 2012.

van Alphen LB, Lemcke Kunoe A, Ceper T, Kahler J, Kjelso C, Ethelberg S, Krogfelt KA.

Euro Surveill. 2015 Jan 29;20(4). pii: 21019. No abstract available.

9.

A receptor-binding protein of Campylobacter jejuni bacteriophage NCTC 12673 recognizes flagellin glycosylated with acetamidino-modified pseudaminic acid.

Javed MA, van Alphen LB, Sacher J, Ding W, Kelly J, Nargang C, Smith DF, Cummings RD, Szymanski CM.

Mol Microbiol. 2015 Jan;95(1):101-15. doi: 10.1111/mmi.12849. Epub 2014 Nov 21.

10.

The application of new molecular methods in the investigation of a waterborne outbreak of norovirus in Denmark, 2012.

van Alphen LB, Dorléans F, Schultz AC, Fonager J, Ethelberg S, Dalgaard C, Adelhardt M, Engberg JH, Fischer TK, Lassen SG.

PLoS One. 2014 Sep 15;9(9):e105053. doi: 10.1371/journal.pone.0105053. eCollection 2014.

11.

Multidisciplinary investigation of a multicountry outbreak of Salmonella Stanley infections associated with turkey meat in the European Union, August 2011 to January 2013.

Kinross P, van Alphen L, Martinez Urtaza J, Struelens M, Takkinen J, Coulombier D, Makela P, Bertrand S, Mattheus W, Schmid D, Kanitz E, Rucker V, Krisztalovics K, Paszti J, Szogyenyi Z, Lancz Z, Rabsch W, Pfefferkorn B, Hiller P, Mooijman K, Gossner C.

Euro Surveill. 2014 May 15;19(19). pii: 20801.

12.

Biological roles of the O-methyl phosphoramidate capsule modification in Campylobacter jejuni.

van Alphen LB, Wenzel CQ, Richards MR, Fodor C, Ashmus RA, Stahl M, Karlyshev AV, Wren BW, Stintzi A, Miller WG, Lowary TL, Szymanski CM.

PLoS One. 2014 Jan 30;9(1):e87051. doi: 10.1371/journal.pone.0087051. eCollection 2014.

13.

Identification of a functional type VI secretion system in Campylobacter jejuni conferring capsule polysaccharide sensitive cytotoxicity.

Bleumink-Pluym NM, van Alphen LB, Bouwman LI, Wösten MM, van Putten JP.

PLoS Pathog. 2013;9(5):e1003393. doi: 10.1371/journal.ppat.1003393. Epub 2013 May 30.

14.

Gene function hypotheses for the Campylobacter jejuni glycome generated by a logic-based approach.

Sternberg MJ, Tamaddoni-Nezhad A, Lesk VI, Kay E, Hitchen PG, Cootes A, van Alphen LB, Lamoureux MP, Jarrell HC, Rawlings CJ, Soo EC, Szymanski CM, Dell A, Wren BW, Muggleton SH.

J Mol Biol. 2013 Jan 9;425(1):186-97. doi: 10.1016/j.jmb.2012.10.014. Epub 2012 Oct 24.

15.

The natural antimicrobial carvacrol inhibits Campylobacter jejuni motility and infection of epithelial cells.

van Alphen LB, Burt SA, Veenendaal AK, Bleumink-Pluym NM, van Putten JP.

PLoS One. 2012;7(9):e45343. doi: 10.1371/journal.pone.0045343. Epub 2012 Sep 25.

16.

Phase variable expression of capsular polysaccharide modifications allows Campylobacter jejuni to avoid bacteriophage infection in chickens.

Holst Sørensen MC, van Alphen LB, Fodor C, Crowley SM, Christensen BB, Szymanski CM, Brøndsted L.

Front Cell Infect Microbiol. 2012 Feb 20;2:11. doi: 10.3389/fcimb.2012.00011. eCollection 2012.

17.

Bacteriophage F336 recognizes the capsular phosphoramidate modification of Campylobacter jejuni NCTC11168.

Sørensen MC, van Alphen LB, Harboe A, Li J, Christensen BB, Szymanski CM, Brøndsted L.

J Bacteriol. 2011 Dec;193(23):6742-9. doi: 10.1128/JB.05276-11. Epub 2011 Sep 30.

18.

Social integration of people with intellectual disability: insights from a social psychological research programme.

Dijker A, van Alphen L, Bos A, van den Borne B, Curfs L.

J Intellect Disabil Res. 2011 Sep;55(9):885-94. doi: 10.1111/j.1365-2788.2011.01446.x. Epub 2011 Jul 5.

PMID:
21726325
19.

Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial.

van Gils EJ, Hak E, Veenhoven RH, Rodenburg GD, Bogaert D, Bruin JP, van Alphen L, Sanders EA.

PLoS One. 2011;6(6):e20229. doi: 10.1371/journal.pone.0020229. Epub 2011 Jun 10.

20.

Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains.

van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Keijzers WC, Bogaert D, Trzcinski K, Bruin JP, van Alphen L, van der Ende A, Sanders EA.

JAMA. 2010 Sep 8;304(10):1099-106. doi: 10.1001/jama.2010.1290.

PMID:
20823436
21.

Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses.

Rodenburg GD, van Gils EJ, Veenhoven RH, Jones N, Tcherniaeva I, Hak E, van Alphen L, Berbers GA, Sanders EA.

Vaccine. 2010 Feb 3;28(5):1391-6. doi: 10.1016/j.vaccine.2009.10.151. Epub 2009 Nov 18.

PMID:
19931382
22.

Portrait of a leading vaccinologist: dedicated to meningitis and respiratory tract infections.

van Alphen L.

Hum Vaccin. 2009 Nov;5(11):722-6. Epub 2009 Nov 5.

PMID:
19855175
23.

Molecular mechanisms of campylobacter infection.

van Putten JP, van Alphen LB, Wösten MM, de Zoete MR.

Curr Top Microbiol Immunol. 2009;337:197-229. doi: 10.1007/978-3-642-01846-6_7. Review.

PMID:
19812984
24.
25.

Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial.

van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Bogaert D, Ijzerman EP, Bruin JP, van Alphen L, Sanders EA.

JAMA. 2009 Jul 8;302(2):159-67. doi: 10.1001/jama.2009.975.

PMID:
19584345
26.

The significance of neighbours: views and experiences of people with intellectual disability on neighbouring.

van Alphen LM, Dijker AJ, van den Borne HH, Curfs LM.

J Intellect Disabil Res. 2009 Aug;53(8):745-57. doi: 10.1111/j.1365-2788.2009.01188.x. Epub 2009 Jun 22.

PMID:
19558458
27.

Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome.

Jansen AG, Rodenburg GD, van der Ende A, van Alphen L, Veenhoven RH, Spanjaard L, Sanders EA, Hak E.

Clin Infect Dis. 2009 Jul 15;49(2):e23-9. doi: 10.1086/600045.

PMID:
19522653
28.

Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.

de Vries JJ, Bungener L, Ter Veer W, van Alphen L, van der Ley P, Wilschut J, Huckriede A.

Vaccine. 2009 Feb 5;27(6):947-55. doi: 10.1016/j.vaccine.2008.11.046. Epub 2008 Dec 4.

PMID:
19059296
29.

A functional Campylobacter jejuni maf4 gene results in novel glycoforms on flagellin and altered autoagglutination behaviour.

van Alphen LB, Wuhrer M, Bleumink-Pluym NM, Hensbergen PJ, Deelder AM, van Putten JP.

Microbiology. 2008 Nov;154(Pt 11):3385-97. doi: 10.1099/mic.0.2008/019919-0.

PMID:
18957592
30.

Meningococcal B vaccine development and evaluation of efficacy.

van Alphen L, van den Dobbelsteen G.

Hum Vaccin. 2008 Mar-Apr;4(2):158-61. Epub 2007 Aug 14.

PMID:
18388494
31.

Active migration into the subcellular space precedes Campylobacter jejuni invasion of epithelial cells.

van Alphen LB, Bleumink-Pluym NM, Rochat KD, van Balkom BW, Wösten MM, van Putten JP.

Cell Microbiol. 2008 Jan;10(1):53-66.

PMID:
18052944
32.

Expression patterns and role of the CadF protein in Campylobacter jejuni and Campylobacter coli.

Krause-Gruszczynska M, van Alphen LB, Oyarzabal OA, Alter T, Hänel I, Schliephake A, König W, van Putten JP, Konkel ME, Backert S.

FEMS Microbiol Lett. 2007 Sep;274(1):9-16. Epub 2007 Jun 15.

34.

Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs.

van den Dobbelsteen GP, van Dijken HH, Pillai S, van Alphen L.

Vaccine. 2007 Mar 22;25(13):2491-6. Epub 2006 Sep 20.

PMID:
17023098
35.

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, Martin D, Zollinger W, Robbins J, Aaberge I, Granoff DM, Miller E, Plikaytis B, van Alphen L, Poolman J, Rappuoli R, Danzig L, Hackell J, Danve B, Caulfield M, Lambert S, Stephens D.

Vaccine. 2006 Jun 12;24(24):5093-107. No abstract available.

PMID:
16838413
36.

A novel phase-variable autotransporter serine protease, AusI, of Neisseria meningitidis.

van Ulsen P, Adler B, Fassler P, Gilbert M, van Schilfgaarde M, van der Ley P, van Alphen L, Tommassen J.

Microbes Infect. 2006 Jul;8(8):2088-97. Epub 2006 Jun 8.

PMID:
16824779
37.

Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.

Bos JM, Rümke HC, Welte R, Spanjaard L, van Alphen L, Postma MJ.

Pharmacoeconomics. 2006;24(2):141-53.

PMID:
16460135
38.

Characterization of genetic and phenotypic diversity of invasive nontypeable Haemophilus influenzae.

Erwin AL, Nelson KL, Mhlanga-Mutangadura T, Bonthuis PJ, Geelhood JL, Morlin G, Unrath WC, Campos J, Crook DW, Farley MM, Henderson FW, Jacobs RF, Mühlemann K, Satola SW, van Alphen L, Golomb M, Smith AL.

Infect Immun. 2005 Sep;73(9):5853-63.

39.

Crystal structure of an Anti-meningococcal subtype P1.4 PorA antibody provides basis for peptide-vaccine design.

Oomen CJ, Hoogerhout P, Kuipers B, Vidarsson G, van Alphen L, Gros P.

J Mol Biol. 2005 Sep 2;351(5):1070-80.

PMID:
16038932
40.

Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.

Welte R, van den Dobbelsteen G, Bos JM, de Melker H, van Alphen L, Spanjaard L, Rümke HC, Postma MJ.

Vaccine. 2004 Dec 9;23(4):470-9.

PMID:
15530695
41.

Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins.

de Jonge MI, Hamstra HJ, Jiskoot W, Roholl P, Williams NA, Dankert J, van Alphen L, van der Ley P.

Vaccine. 2004 Sep 28;22(29-30):4021-8.

PMID:
15364452
42.

PorA-specific differences in antibody avidity after vaccination with a hexavalent Men B outer membrane vesicle vaccine in toddlers and school children.

Vermont CL, Van Dijken HH, De Groot R, Van Alphen L, Van Den Dobbelsteen GP.

Vaccine. 2004 Aug 13;22(23-24):3008-13.

PMID:
15297049
43.

A Neisserial autotransporter NalP modulating the processing of other autotransporters.

van Ulsen P, van Alphen L, ten Hove J, Fransen F, van der Ley P, Tommassen J.

Mol Microbiol. 2003 Nov;50(3):1017-30.

44.

Mapping the binding domains on meningococcal Opa proteins for CEACAM1 and CEA receptors.

de Jonge MI, Hamstra HJ, van Alphen L, Dankert J, van der Ley P.

Mol Microbiol. 2003 Nov;50(3):1005-15.

45.

Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form.

Luijkx TA, van Dijken H, Hamstra HJ, Kuipers B, van der Ley P, van Alphen L, van den Dobbelsteen G.

Infect Immun. 2003 Nov;71(11):6367-71.

46.

Lipoprotein signal peptidase of Streptococcus suis serotype 2.

De Greeff A, Hamilton A, Sutcliffe IC, Buys H, Van Alphen L, Smith HE.

Microbiology. 2003 Jun;149(Pt 6):1399-407.

PMID:
12777481
47.

Immunogenicity of peptide-vaccine candidates predicted by molecular dynamics simulations.

Oomen CJ, Hoogerhout P, Bonvin AM, Kuipers B, Brugghe H, Timmermans H, Haseley SR, van Alphen L, Gros P.

J Mol Biol. 2003 May 16;328(5):1083-9.

PMID:
12729743
48.

Functional activity of antibodies against the recombinant OpaJ protein from Neisseria meningitidis.

de Jonge MI, Vidarsson G, van Dijken HH, Hoogerhout P, van Alphen L, Dankert J, van der Ley P.

Infect Immun. 2003 May;71(5):2331-40.

49.

Mucin in middle ear effusions inhibits attachment of Haemophilus influenzae to mucosal epithelial cells.

Solzbacher D, Hanisch FG, van Alphen L, Gilsdorf JR, Schroten H.

Eur Arch Otorhinolaryngol. 2003 Mar;260(3):141-7. Epub 2002 Oct 3.

50.

Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.

Vermont CL, van Dijken HH, Kuipers AJ, van Limpt CJ, Keijzers WC, van der Ende A, de Groot R, van Alphen L, van den Dobbelsteen GP.

Infect Immun. 2003 Apr;71(4):1650-5.

Supplemental Content

Loading ...
Support Center